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Abstract: Thyroid nodules are less frequent in children than adults. Childhood thyroid nodules 
carry specific features, including a higher risk of malignancy than nodules in adults, rendering 
them unique in terms of management. Subsequently, they should be considered a distinct clinical 
entity with specific imaging recommendations. Initial evaluation requires a thorough workup, 
including clinical examination, and a detailed personal and familial history to determine the 
presence of possible risk factors. Laboratory and radiologic evaluation play an integral part in the 
diagnostic algorithm, with ultrasonography (US) being the first diagnostic test in all patients. US 
elastography has been recently introduced as an incremental method, reducing the subjectivity of 
the clinical diagnosis of nodule firmness associated with increased malignancy risk. However, 
fine-needle aspiration biopsy (FNAB) remains the mainstay in the diagnostic work-up of thyroid 
nodules and is documented to be best method for differentiating benign from malignant thyroid 
nodules. In addition, thyroid scintigraphy provides functional imaging information, which has a 
role both in the diagnostic management of thyroid nodules and during follow up in malignancies. 
Finally, despite providing additional information in certain clinical scenarios, 18F-fludeoxyglucose 
Positron Emission Tomography (18F-FDG-PET), computed tomography (CT), and magnetic 
resonance imaging (MRI) imaging are not routinely recommended for the evaluation of patients 
with newly detected thyroid nodules or in all cases of thyroid cancer. The objective of this review is 
to summarize the concepts in imaging and imaging-based management of nodular thyroid disease 
in the pediatric population, acknowledging the unique features that this patient group carries and 
the specific approach it requires. 
Keywords: thyroid nodules; thyroid cancer; children; imaging; ultrasound; elastography; fine 
needle aspiration biopsy (FNAB), scintigraphy 
 
1. Introduction—Definitions 
Thyroid nodules have been defined by the American Thyroid Association (ATA) as “discrete 
lesions within the thyroid gland, radiologically distinct from surrounding thyroid parenchyma” [1]. 
They may be discovered by palpation during a general physical examination or with imaging 
modalities performed for medical evaluations, such as ultrasound (US), computed tomography (CT) 
scans, magnetic resonance imaging (MRI) studies, or 18F-fludeoxyglucose Positron Emission 
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Tomography (18F-FDG-PET) scanning. The latter entities are called thyroid incidentalomas and they 
generally do not correspond to palpable thyroid lesions. Conversely, clinicians may identify 
palpable thyroid lesions that do not correspond to distinct radiological entities, and therefore would 
not be defined as thyroid nodules [2].  
Compared to adults, thyroid tumors in children are larger and have a greater incidence of 
lymph node and lung metastases. Moreover, pediatric thyroid tumors are characterized by a higher 
recurrence rate. However, the overall prognosis for cancer death is much better in 
children.According to the latest ATA guidelines (GLs) on management for children with thyroid 
nodules and differentiated thyroid cancer (DTC), in order to more accurately define the impact of 
the physiological changes of growth and development on thyroid tumor behavior in this patient 
group, the upper age limit for pediatrics should be defined as patients ≤ 18 years of age, since the 
majority of children have completed development by this age [3].  
2. Epidemiology 
Both thyroid nodules and cancer are less common in children than adults. Nodule prevalence is 
estimated to be 0.2%–5% in children compared with 19%–35% in adults [4]. However, pediatric 
thyroid nodules have a higher likelihood of malignancy compared with those in adults (25% versus 
10%, respectively) [5]. 
Relative to the common pediatric malignancies, such as leukemia, central nervous system 
(CNS) tumors, and lymphoma, thyroid cancer is rare in pediatric populations, affecting 
approximately 1 in every 1000 to 2000 children in the United States. However, it is the leading cause 
of pediatric endocrine cancer, accounting for over 6% of all pediatric cancers [6]. The incidence of 
thyroid cancer is increased in young adults, accounting for 13% of all invasive neoplasms [7]. 
Thyroid carcinomas in childhood are almost always well-differentiated. Recently, a 
multicentric study conducted on 120 pediatric patients with a thyroid nodule not associated with 
risk factors such as autoimmune thyroid diseases or radiotherapy revealed a 16% occurrence of 
thyroid carcinoma (73.7% papillary, 15.8% follicular, 10.5% medullary histotypes) [8]. 
According to the Surveillance Epidemiology and End Results (SEER) Cancer Registries, the 
estimated new cases of thyroid cancers in 2019 were 52,070 (1.8% of age <20 years old), while the 
estimated deaths attributed to the malignancy reached 2,170 (0.1% patients <20 years old) 
(https://seer.cancer.gov/statfacts/html/thyro.html, accessed on 27 January 2020). In Europe, an 
estimated 52,956 thyroid cancer (TC) cases were newly diagnosed in 2012, according to the latest 
records of the International Agency for Research on Cancer of the World Health Organization, 
(European Cancer). In the same year, 6336 Europeans were estimated to have died of TC 
(http://eco.iarc.fr/eucan/Cancer.aspx?Cancer=35, accessed on 12 December 2019). Thyroid cancer is 
more common in females than males. Based on the SEER registries, the age-standardized incidence 
rates (1987–1991) for thyroid cancer were 2.5 per 100,000 for males and 6.4 per 100,000 for females. 
Apart from this gender difference, racial variability is also observed, with Asians being more likely 
to be diagnosed with thyroid cancer, followed by whites and blacks [9]. In pediatric populations in 
particular, the National Cancer Institute's SEER database was queried for all cases of pediatric 
thyroid cancer between the years 2007 and 2012 by Dermody et al. The authors showed that despite 
an annual increase in its incidence of approximately one percent, pediatric thyroid carcinoma 
remained an uncommon diagnosis. According to their results the average age-adjusted rate of 
malignancy was 0.59 per 100,000 patients, with a female to male ratio of 4:1 [10]. 
Contrary to Dermody’s results, Qian et al. showed that the increase of the annual percent 
change (APC) of pediatric thyroid carcinoma in the last years reached +4.6% between 1996 and 2016 
[11]. The increase in incidence rates was similarly mirrored by increases in incidence rates for 
papillary histologic subtype, female sex, and adolescent age. Pediatric thyroid cancer incidence 
trends did not vary by tumor size or extent of disease. One important reason for this higher 
incidence of the malignancy is the steadily growing usage of more sensitive imaging techniques, as 
well the enhanced performance of fine-needle aspiration biopsies (FNAB), which enable the 
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detection of small, indolent tumors, including incidental microcarcinomas sometimes of 
questionable clinical significance. 
Besides their particular epidemiological characteristics, childhood thyroid nodules also carry 
some features which render them unique in terms of management: they seem to be affected 
differently by potential risk factors, they have other histological characteristics, they show frequent 
and precocious lymph node metastases when malignant as well as different clinical features 
compared with adults, and harbor specific molecular anomalies [11]. Such differences stress the 
particularity of the pediatric thyroid nodules, which should be subsequently considered a distinct 
clinical entity with specific imaging recommendations. 
Having these in mind and considering the concerns raised by the continuously increasing usage 
of imaging techniques, which has led to unprecedented rates of incidental diagnosis of thyroid 
nodules; thus, raising the issue of potential overdiagnosis of pediatric thyroid cancer, we aim in this 
review article to present the main data published in the field of imaging of pediatric thyroid nodules. 
3. Risk Factors for Thyroid Nodules and Factors Indicative of Higher Malignancy Risk 
Risk factors for thyroid nodules in children include family history of thyroid nodules or thyroid 
cancer, iodine deficiency, radiation exposure, history of thyroid disease, elevated serum thyrotropin 
(TSH), gender, race, age, and several genetic syndromes (Table 1) [12–14]. 
Table 1. Risk factors for thyroid nodules and factors indicative of higher malignancy risk. 
Exposure to radioactivity 
Medical exposure 
External beam radiation therapy 
Radioactive contamination 
Genes’ mutations andrelated types of thyroid tumors 
RET:MTC 
HRAS, KRAS, NRAS: FTA, FTC, FVPTC, PDTC, ATC 
PI3KCA: FTA, FTC, ATC, PTC 
AKT1: Metastatic cancer 
CTNNB1: PDTC, ATC 
TP53: PDTC, ATC 
PPKAR1A: PTC, HCTC 
IDH1: FTC, FVPTC, PTC, ATC 
ALK: ATC 
APC: NMTC 
EGFR: PTC 
BRAFV600E: PTC, FVPTC, TCPTC,ATC 
BRAFK601E: FVPTC 
PTEN (mutation): FTCA, FTC, ATC, PTC 
PTEN (deletion): FTC 
NDUFA13: HCTC 
Benign thyroid diseases 
Autoimmune thyroiditis, most commonly Hashimoto 
Goiter 
Grave’s disease 
Iodine consumption 
Dietary and Metabolic factors 
Obesity 
Lack of physical exercise 
Smoking 
Female sex 
Gender hormones and reproductive function 
Menstruation before the age of 12 or after 14 years 
Gestation 
Exogenous hormones 
Trace elements associated with volcanic activity 
Environmental factors 
Air pollutants 
Xenobiotics 
Viruses 
ALK, anaplastic lymphoma kinase; APC, adenomatous polyposis coli; ATC, anaplas ticthyroid 
cancer; EGFR, epidermal growth factor receptor; FTA, follicular thyroid adenoma; FTC, follicular 
thyroid cancer; FVPTC, follicular-variant PTC; HCTC, Hürthle cell thyroid cancer; IDH1, isocitrate 
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dehydrogenase 1; NDUFA13, NADH dehydrogenase (ubiquinone) 1α subcomplex 13; NMTC, 
non-medullary thyroid carcinoma; PDTC, poorly differentiated thyroid cancer; PTC, papillary 
thyroid cancer; TCPTC, tall-cell PTC. 
Approximately 41% of children with thyroid nodules have a family history of thyroid 
disorders. Familial association is observed in 5% of all thyroid cancers with a follicular cell origin 
and 25% of those with parafollicular cell origin. Familial thyroid cancer from follicular cells is 
usually more aggressive than its sporadic form in terms of increased risk of recurrence and a 
younger age of onset. Familial non-medullary thyroid cancer may be associated with several 
syndromes, such as Carney’s complex (PPKAR1A gene mutation), Cowden’s syndrome (PTEN gene 
mutation), and familial adenomatous polyposis (FAP) (APC gene mutation). In particular, thyroid 
nodules are present in 67% of children presenting with Carney’s complex, and thyroid carcinoma is 
observed in 3.8% of patients. A total of 1%–2% of patients with FAP, an inherited familial cancer 
characterized by an increased predisposition to colonic and extracolonic neoplasias, have thyroid 
carcinoma. Among childhood thyroid carcinomas of non-follicular origin, medullary thyroid cancer 
(MTC) is of familial origin in approximately 20% of patients. These cases are associated with a 
germline RET (ret proto-oncogene) mutation. Familial MTC may occur in isolation or as a part of 
multiple endocrine neoplasia (MEN) type II syndrome [15]. 
Thyroid nodules are often associated with other thyroid diseases, such as Hashimoto thyroiditis 
(HT), implying a causative relationship. A plethora of studies regarding the potential association 
between HT and thyroid cancer development have been carried out in adults. Most of them have 
demonstrated that the coexistence of HT and thyroid tumors—mainly papillary thyroid cancer 
(PTC)—is common, and that the risk of the development of thyroid cancer is significantly higher in 
patients with HT than in those without HT. Interestingly, HT seems to have a certain protective 
effect on the short- and long-term prognosis of cancer. In children, the available studies are few and 
with rather serious methodological limitations. However, similar to adults, the association between 
HT and thyroid cancer is also relatively common in children and adolescents. According to the 
results of these studies, the frequency of PTC in children and adolescents with HT is variable, from 
0.7 to ~3%, while in patients with PTC the prevalence of coexisting HT varies from 6.3% to more than 
40% of the cases. In a study including 108 pediatric thyroid cancer cases, HT was detected in 28.7% 
of the enrolled patients [16]. Furthermore, congenital hypothyroidism caused by 
dyshormonogenesis or by an iodine transporter defect increases the risk of nodules in children that 
can evolve to thyroid cancer of the follicular type [16]. 
A causal association between external radiation exposure and thyroid cancer is strongly 
supported by epidemiologic studies, since the young thyroid gland is particularly radiosensitive. 
Since 1995, the amount of information on thyroid cancer and childhood radiation exposure has 
increased substantially. Many of the original cohorts have extended their follow-ups and 
investigators have reported several new studies, resulting in a commensurate increase in the number 
of reported thyroid cancer cases. Previous studies showed an elevated risk for thyroid cancer in 
childhood cancer survivors who were treated for their primary malignancy with radiation therapy, 
especially Hodgkin lymphoma, leukemia, and central nervous system tumors [17,18]. However, 
smaller radiation doses were previously also used for non-cancer disorders in infants and children, 
such as enlarged thymus glands, enlarged tonsils, adenoids, and acne. Thyroid cancer from 
radiation exposure may occur as soon as 5–10 years after treatment and may persist for patients for 
50 years or more after irradiation, with higher doses of radiation exposure seeming to be associated 
with an increased risk of cancer occurrence. Nevertheless, there is some variability in this result. 
Interestingly, high radiation doses were associated with a lower risk of malignancy, probably 
because high doses are likely to cause cell death. Besides radiation, chemotherapy drugs cause a 
four-fold increased risk of thyroid cancer [19,20]. 
Variations in population iodine intake are a primary determinant of benign thyroid disorders, 
such as goiters, nodules, and hyper- or hypothyroidism. Nowadays, it is clear that iodine deficiency 
sharply increases the risk of nodules and goiters in populations. However, the role of iodine intake 
J. Clin. Med. 2020, 9, 384 5 of 15 
  
in thyroid cancer remains uncertain, despite decades of study and debate. Several mechanisms 
linking iodine intake and thyroid cancer have been proposed, including chronic TSH stimulation, 
increase of H2O2-mediated, reactive oxygen species (ROS) generation, which can damage DNA and 
result in mutations, as well as associations with BRAF and RAS mutations [21].  
Pediatric patients carrying such risk factors might benefit from prospective screening for 
thyroid nodules and thyroid cancer. According to the respective GLs, an annual physical 
examination is recommended in children at high risk for thyroid neoplasia, while additional 
imaging should be pursued if palpable nodules, thyroid asymmetry, and/or abnormal cervical 
lymphadenopathy are found on examination [3]. 
4. Initial Evaluation 
A detailed personal and familial medical record to determine the presence of any of the 
aforementioned potential risk factors (positive family history, iodine deficiency, prior radiation 
exposure, history of thyroid disease, elevated TSH, gender, race, age, genetic syndromes) is 
mandatory, before physical, laboratory, and imaging examinations take place. Although 
physician-dependent, palpation gives the main idea about the location, size, consistency, and 
motility of the nodule. Despite the fact that there is no critical size for a nodule to be palpated, 
usually nodules >1.5 cm are palpable. Tenderness of the thyroid gland should be noted, as well as 
pain, changes over time, growth, and possible fixation to surrounding structures. In general terms, a 
large hard nodule, especially one adherent to adjacent tissue, is concerning for cancer [22]. As 
mentioned above, an annual physical examination is recommended in children at high risk for 
thyroid neoplasia, potentially with additional imaging. Regarding patients at increased risk of 
developing familial DTC, they should be referred to specialized centers so that appropriate 
evaluation, follow-up, genetic counseling, and/or treatment can be undertaken without subjecting 
patients and families to unwarranted and aggressive treatments [3]. 
Laboratory evaluation of the thyroid nodule includes serum TSH, T3, T4, AntiTPO antibodies, 
and calcitonin measurements.  Serum TSH should be measured during the initial evaluation of a 
patient with a thyroid nodule. A higher serum TSH level, even within the upper part of the reference 
range, is associated with increased risk of malignancy in a thyroid nodule, as well as a more 
advanced stage of thyroid cancer [23]. T3, T4, and antiTPO antibodies evaluation is not routinely 
indicated unless hyperthyroidism is suspected, while calcitonin should be measured in high-risk 
patients for MTC (known mutation). Finally, in cases of known malignancy Tg and basal calcitonin 
may serve as biochemical tumor markers used postoperatively for surveillance. Calcitonin 
stimulating tests with Ca2+or pentagastrin are very useful, both for excluding an MTC when basal 
calcitoninis in the grey zone (15–50 ng/L) and for detecting residual disease or recurrence after 
surgery for MTC in patients with low basal levels [15]. 
5. Ultrasonography (US) 
Imaging of thyroid nodules plays an integral part of the diagnostic algorithm. Being 
noninvasive, inexpensive, and highly sensitive, US is recommended as the first diagnostic test in all 
children with thyroid nodules. The US report should convey nodule size and location and a 
description of the nodule’s sonographic features, including composition (solid, cystic proportion, or 
spongiform), echogenicity (hyper-, iso-, hypoechoic), margins (smooth, irregular, lobulated, 
ill-defined, Halo, extrathyroid extension), presence and type of calcifications, shape, if taller than 
wide, and vascularity. The pattern of sonographic features associated with a nodule confers a risk of 
malignancy and, combined with nodule size, guides FNAB decision-making [24]. In general, the US 
features most concerning for malignancy are hypoechogenicity, irregular margins, and increased 
intranodular blood flow, as well as the presence of microcalcifications and abnormal cervical lymph 
nodes. On the other hand, entirely cystic nodules are regarded as almost always benign [3,25,26]. 
Notably, apart from the greater probability of DTC (22–26%) in pediatric populations, 
differences exist between children and adults regarding the frequency of DTC subtypes. For 
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example, children and adolescents may have a widely invasive form of PTC called diffuse sclerosing 
variant PTC, which has abundant microcalcifications on US but usually not discrete thyroid nodules. 
For such reasons, in children, US-guided FNAB should be performed in all thyroid nodules of more 
than 10mm, unless purely cystic, and in thyroid nodules 5–10mm with suspicious US features. 
FNAB of suspicious lymph nodes with a thyroglobulin measured on the needle washout should also 
be performed prior to performing a lateral neck lymph node dissection [4]. 
Several studies have investigated the sonographic features of malignant pediatric thyroid 
nodules [8,25–29]. In the largest and most detailed series, including 404 nodules in 314 children, 
Richman et al. showed that most of the sonographic characteristics of a nodule associated with 
increased risk of cancer in adults also convey a higher risk of malignancy in children. In particular, 
the presence of speckled calcifications, irregular margins, taller-than-wide shape, and abnormal 
lymph nodes conveyed an increased cancer risk. Moreover, similarly to adults, solid nodules as well 
as solitary nodules were more likely to be malignant. On the contrary, unlike adults, in whom size is 
not associated with increased malignancy risk, in their series the malignancy rate increased with 
increasing nodule size. In addition, patients with an abnormal background sonographic appearance 
documented a higher risk of malignancy as compared to patients with normal background gland 
echo texture. Furthermore, certain US characteristics, including a taller-than-wide shape, presence of 
calcifications, and presence of abnormal lymph nodes, showed fairly high specificity but only 
moderate sensitivity for malignancy, confirming the—documented in adults—insufficiency of 
sonographic evaluation alone in enabling differentiation between benign and malignant thyroid 
nodules. Interestingly, with regards to color Doppler analysis, it was found to be not a useful 
differentiating characteristic in the identification of thyroid cancer [30]. 
ATA’s panel does not recommend US screening of the thyroid even in children carrying some 
factors associated with higher malignancy risk, such as those with a history of radiation exposure to 
the thyroid. The main reason for this is that the impact of the detection of subclinical disease by US 
prior to a palpable abnormality on the long-term outcome of these patients is not clear. On the other 
hand, evaluation by an experienced thyroid ultrasonographer should take place in children with 
autoimmune thyroiditis and a suspicious thyroid examination (suspected nodule or significant 
gland asymmetry), especially if associated with palpable cervical lymphadenopathy [3].The 
sonographic patterns of thyroid nodules and theirestimated risk of malignancy as well as the main 
differences between pediatric and adult thyroid nodules are concisely described in Table 2. 
Table 2. Characters of thyroid nodules and differences between children and adults thyroid 
nodules. 
A. Sonographic patterns of thyroid nodules and estimated risk of malignancy [24]. 
Sonographic Pattern US Features Estimated Risk of Malignancy 
High suspicion 
Solid hypoechoic nodule or solid 
hypoechoic component of a partially 
cystic nodule with one or more of the 
following features: irregular margins 
(infiltrative, microlobulated), 
microcalcifications, taller-than-wide 
shape, rim calcifications with small 
extrusive soft tissue component, 
evidence of extrathyroidal extension 
>70%–90% 
Intermediate suspicion 
Hypoechoic solid nodule with smooth 
margins without microcalcifications, 
extrathyroidal extension, or taller-than-wide 
shape 
10%–20% 
Low suspicion 
Isoechoic or hyperechoic solid nodule, 
or partially cystic nodule with 
eccentric solid areas, without 
microcalcification, irregular margin or 
extrathyroidal extension, or taller-than-wide 
shape. 
5%–10% 
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Very low suspicion 
Spongiform or partially cystic nodules 
without any of the sonographic 
features described in low, 
intermediate, or high suspicion 
patterns 
<3% 
Benign Purely cystic nodules (no solid component) <1% 
B. Differences between pediatric and adult thyroid nodules 
Difference Pediatric Adults 
Epidemiology [4,5] 
Less common. Nodule prevalence: 0.2%–5% 
More common 
Nodule prevalence: 19%–35% 
Higher likelihood of malignancy (25%) Lower likelihood of malignancy (10%) 
Histology/Stage[3] 
Higher incidence of regional lymph node 
involvement, 
extrathyroidal extension, and pulmonary 
metastasis 
Lower incidence of regional lymph node 
involvement, 
extrathyroidal extension, and pulmonary 
metastasis 
Prognosis[11] 
More favorable progression-free survival in 
children 
Mortality rate~0.1% in patients aged< 20 
Less favorable progression-free survival in 
adults 
Maximum mortality rate up to 27.4% in 
patients aged 75–84 
Molecular[3] 
Higher prevalence of gene rearrangements and 
a lowerfrequency of point mutations in the 
proto-oncogenes implicatedin PTC 
Lower prevalence of gene rearrangements and 
a higherfrequency of point mutations in the 
proto-oncogenes implicatedin PTC 
BRAF mutations are the less common 
abnormality in children PTC  
BRAF mutations are the most common 
abnormality in adult PTC (36%–83% of cases) 
RET/PTC rearrangements 
are more common in PTC from children 
RET/PTC rearrangements 
are less common in adult PTC  
Sonographic 
characteristics 
[8,25–29] 
The malignancy rate is increased with 
increasing nodule size 
The nodule’s size is not associated with 
increased malignancy risk 
Color Doppler analysisis not a useful 
differentiating characteristic in the 
identification of thyroid cancer  
Color Doppler analysis has incremental value 
in the identification of malignancies 
Patients with an abnormal background 
sonographic appearance documented a higher 
risk of malignancy 
A higher risk of malignancy is not documented 
for patients with an abnormal background 
sonographic appearance 
Diffuse sclerosing variant PTC, with abundant 
microcalcifications is more common in children 
Diffuse sclerosing variant PTC with abundant 
microcalcifications is less common in adults 
6. US Elastography 
Elastography is a novel, noninvasive imaging technique for the US evaluation of the mechanical 
properties (elasticity) of different types of tissue. Particularly in thyroid nodule diagnostics, US 
elastography was introduced as a method reducing the subjectivity of the clinical diagnosis of 
nodule firmness associated with increased malignancy risk. In general, it acquires information on 
the movement of the tissue in response to the application of a small amount of pressure: in softer 
tissues, the applied pressure causes the tissue to compress more, whereas harder tissues compress 
less [31]. 
Two methods are used for determining nodule stiffness: strain elastography, in which force is 
applied to the tissue by manual compression and the tissue deformation is parallel to the direction of 
the force, and shear-wave elastography (SWE), in which a push beam is created and the tissue 
deformation is perpendicular to the direction of the force [32]. Colors around and within the nodules 
are evaluated and visually scored according to a 4- to 5-scale scoring system, the regions of interest 
being specified as the target lesion and the adjacent reference region. The strain ratio is calculated 
automatically, and a higher strain ratio translates to a higher probability of malignancy. Another 
form of evaluating the elastography data is by calculating the thyroid strain ratio to perform an 
objective, semi-quantitative analysis of the tissue stiffness [33]. 
Despite the increasing number of studies assessing the diagnostic value of elastography in 
adults, only a few of them focus on children with thyroid nodules, mainly due to specific problems 
concerning the use of the technique in the pediatric population, since the compressive nature of 
elastography induces discomfort in children [26]. Furthermore, the rarity of pediatric thyroid 
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nodules in general causes a shortage in the study population needed to truly determine the 
importance of US elastography [34]. Notably, in a study by Rago et al., elastography could increase 
the accuracy of US in thyroid nodule differentiation regardless of the nodule size [35].  
Importantly, in recent years the efficacy of elastography has been investigated in the thyroid 
gland of healthy subjects as well as of children with several thyroid pathologies. Yurttutan et al. 
assessed a baseline strain index for healthy pediatric thyroid tissue and determined a mean value of 
0.54 ± 0.38 m/s for normal pediatric thyroid tissue relative to adjacent soft tissue at the same depth, 
with no significant difference between subjects on the basis of sex, age, weight, height, or body mass 
index [36]. BakırtaşPalabıyık et al. measured the elasticity of thyroid tissue in children and 
adolescents using SWE and investigated the role of SWE in the diagnosis of autoimmune thyroiditis 
in childhood. Quantitative elastographic analysis evaluated by SWE in autoimmune thyroiditis 
patients (3.7 ± 1.2 m/s) was significantly higher compared with normal pediatric patients (1.8±0.3 
m/s) and the optimal cut-off value was 2.39 m/s [37]. In parallel, with their recent study Cunha et al. 
evaluated the usefulness of strain elastography as an additional diagnostic tool for children who 
present with thyroid nodules. The authors found that the high elasticity of a nodule on elastography 
was associated with a low risk of thyroid cancer [33]. In agreement with them, Borysewicz-Sanczyk 
et al. found elastography to have a high negative predictive value for a benign diagnosis, by 
analyzing a total of 62 thyroid nodules in 47 children and adolescents [38]. Such studies suggest that 
the method may prove useful as a complementary test for screening thyroid nodules in children. 
7. Fine-Needle Aspiration Biopsy (FNAB) 
FNAB of a thyroid nodule is the best method for differentiating benign from malignant thyroid 
nodules and diffuse goiters. FNAB has long been the mainstay in the diagnostic work-up of adult 
thyroid nodules, and recent literature supports its efficacy in the pediatric population, with reported 
accuracy, sensitivity, and specificity of 99%, 94%, and 100%, respectively, per one recent study [39]. 
FNAB is a minor outpatient procedure performed in awake, non-fasting patients with appropriate 
aseptic technique, while local anesthesia is optional. FNAB can also be useful to evacuate cystic 
lesions, although the fluid will recollect in one-half of these cysts. To address terminology and other 
issues related to thyroid FNA, the National Cancer Institute (NCI) hosted the NCI Thyroid FNA 
State of the Science Conference. The conclusions regarding terminology and morphologic criteria 
from the NCI meeting led to the Bethesda Thyroid Atlas Project and formed the framework for The 
Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). For clarity of communication, 
TBSRTC recommends that each report begin with one of six general diagnostic categories (Table 3) 
[40]. 
Table 3. [40]The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). 
I Non-diagnostic or unsatisfactory 
Cyst fluid only 
 Virtually acellular specimen 
 Other (obscuring blood, clotting artifact, etc.) 
II Benign 
Consistent with a benign follicular nodule (includes 
adenomatoid nodule, colloid nodule, etc.) 
 Consistent with lymphocytic (Hashimoto) thyroiditis in 
the proper clinical context 
 Consistent with granulomatous (subacute) thyroiditis 
 Other 
III Atypia or follicular lesion of undetermined significance (AUS/FLUS). 
IV 
Follicular/Hürthle neoplasm or suspicious for 
follicular/Hürthle neoplasm (FN or SFN) 
Specify if Hürthle cell (oncocytic) type 
V Suspicious for malignancy (SUSP) 
Suspicious for papillary carcinoma 
 Suspicious for medullary carcinoma 
 Suspicious for metastatic carcinoma 
 Suspicious for lymphoma 
 Other 
VI Malignant Papillary thyroid carcinoma 
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 Poorly differentiated carcinoma 
 Medullary thyroid carcinoma 
 Undifferentiated (anaplastic) carcinoma 
 Squamous cell carcinoma 
 Carcinoma with mixed features (specify) 
Metastatic carcinoma 
 Non-Hodgkin lymphoma 
 Other 
Although there is significant variability between studies, the risk of malignancy in 
non-diagnostic (Bethesda I), benign (Bethesda II), and suspicious/malignant (Bethesda V/VI) mirrors 
adult risk assessment at 0% (range 0–10%), 5%–8% (range 0–16%), and 100%, respectively (Bethesda 
V range: 40%–100%, Bethesda VI range: 100%). Several studies suggest that Bethesda III and IV 
categories account for up to 40% (range: 13%–43%) of all pediatric FNAB diagnoses. Furthermore, 
these indeterminate aspirate diagnoses are associated with increased risk of malignancy in children 
versus adults (28% in children versus 6%–30% in adults for atypia or follicular lesion of 
undetermined significance (AUS/FLUS) and 58% in children versus 10%–40% in adults for 
follicular/Hürthle neoplasm or suspicious for follicular/Hürthle neoplasm (FN/SFN lesions). 
However, more recent studies indicate lower percentages of indeterminate FNAB groups than 
previously reported (13%–18% for indeterminate diagnoses combined) and a lower risk of 
malignancy after histologic resection within these groups (11%–20% for AUS/FLUS; 25%–28% for 
FN/SFN) [6]. 
Cherella et al. investigated the differences in thyroid nodule cytology and malignancy risk 
between children and adults and found that pediatric nodules were more likely to be malignant than 
adult ones (19% versus 12%). Within cytological categories, malignancy rates were higher in 
pediatric nodules than in adult nodules that were cytologically non-diagnostic, atypia of 
undetermined significance (44% versus 22%), or suspicious for follicular neoplasm (71% versus 
28%). No significant differences were observed between children and adults in the types of thyroid 
cancers diagnosed in these cytological categories. Malignancy rates did not differ between children 
and adults among nodules with cytology suspicious for papillary carcinoma or positive for 
malignancy. In this respect, their findings provide pediatric-specific data to inform the optimal 
management of thyroid nodules in children, which may differ from that of adult nodules with 
equivalent cytology [41]. 
As far as the performance of FNAB in children is concerned, ATA GLs recommend the same 
evaluation and treatment of thyroid nodules in children as in adults, with the following exceptions: 
(a) for the identification of nodules that warrant FNA, US characteristics and clinical context should 
be applied rather than size alone, (b) FNA should be performed under US guidance in children, (c) 
preoperative FNA of a hyperfunctioning nodule in a child is not warranted as long as the lesion is 
removed, (d) a diffusely infiltrative form of PTC may occur in children and should be considered in 
a clinically suspicious gland, and (e) for most nodules with indeterminate cytology, surgery is 
favored over repeat FNAB [3]. 
8. 123Ι/131Ι/99mTc Thyroid Scintigraphy 
Thyroid scintigraphy provides functional imaging of the gland based on the fact that thyroid 
follicular cells concentrate iodine efficiently. Both 99mTc-pertechnetate (99mTcO4-) and iodine-123/131 
(123I and 131I) can be used for thyroid imaging. Iodine is taken up by thyroid follicular cells via the 
sodium-iodine symporter (NIS), is organified and then incorporated into thyroid hormones. 
99mTcO4-, on the other hand, is taken up by the thyroid but is not organified, and is thus not ideal for 
thyroid uptake calculations. Evaluation of pediatric thyroid nodules via radioiodine or 
99mTcO4-thyroid scintigraphy has largely been replaced by high resolution US. Nevertheless, 
according to the European Association of Nuclear Medicine/Society of Nuclear Medicine and 
Molecular Imaging (EANM/SNMMI )practice guideline procedure standard for radioiodine uptake 
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(RAIU) and thyroid scintigraphy, scintigraphy still has a role in evaluating the following: function of 
thyroid nodules detected on clinical examination and/or other imaging examinations classifying 
them into hyper-, iso-, or non-functioning nodules, multinodular goiter to identify suspicious 
hypofunctional “cold” areas that require further evaluation with FNAB or hyperfunctional “hot” 
thyroid nodules prior to radioiodine ablation [42]. Briefly, hyperfunctioning nodules do not require 
further cytologic evaluation, since they rarely harbor malignancy; nevertheless, indeterminate 
cytology (e.g., Bethesda classes III and IV, see below) is frequently reported in these cases. However, 
patients with overt or subclinical hypothyroidism as well as those with serum TSH, within the upper 
part of the reference range require further evaluation [23]. According to the ATA GLs, thyroid 
scintigraphy should be pursued for pediatric patients with a suppressed TSH associated with a 
thyroid nodule. Increased uptake within the nodule is consistent with autonomous nodular function 
and thyroid scintigraphy is the only examination able to demonstrate the presence of autonomously 
functioning thyroid nodules [3].  
9. PET/CT 
18FDG-PET imaging is not recommended for the evaluation of patients with newly detected 
thyroid nodules or thyroidal illness. Nonetheless, a focal or diffuse incidental detection of abnormal 
thyroid uptake may be encountered. In particular, focal 18F-FDG-PET uptake in the thyroid is 
incidentally detected in 1–2% of adult patients, while an additional 2% of patients demonstrate 
diffuse thyroid uptake [24]. Moreover, 18F-FDG-PET imaging is not routinely recommended for the 
evaluation of thyroid nodules with indeterminate cytology, despite the fact that several studies in 
the adult population have been published, examining the role of 18F-FDG-PET in the preoperative 
assessment of such nodules [43–46]. In a meta-analysis including seven studies, the sensitivity and 
specificity of 18F-FDG-PET were 89% and 55%, respectively, resulting in a 41% positive predictive 
value (PPV) and 93% negative predictive value (NPV), which is similar to the performance of the 
Gene Expression Classifier (GEC) [47]. Vriens et al. performed a cost-effectiveness analysis using 
18F-FDG-PET performance data from their own meta-analysis and 2012 reimbursement rates of the 
Dutch system. They showed that 18F-FDG-PET was more cost-effective than surgery, the GEC, or 
mutational testing [48]. Recently, a prospective analysis of 87 adult patients who were scheduled to 
undergo surgery for thyroid nodule with indeterminate cytology used 18F-FDG-PET, 
multiparametric neck ultrasonography (MPUS), and 99mTc-sestamibi (MIBI) scan to further evaluate 
thyroid nodules. The authors demonstrated that the accuracy of 18F-FDG-PET/CT in detecting 
thyroid malignancy is higher than that of 99mTc-MIBI-scan and MPUS. According to their results, a 
negative 18F-FDG-PET/CT correctly predicts benign findings on histopathology. The association of 
FDG+/MPUS+ is significantly more specific than 18F-FDG-PET/CT alone in identifying DTC. A 
positive 18F-FDG-PET/CT is significantly associated with malignancy when the qualitative 
99mTc-MIBI-scan is rated as negative [49]. However, the modality cannot be routinely recommended 
in the care of children who have persistent evidence of DTC on follow-up [3]. Moreover, PET/CT 
with tracers other than 18F-FDG, such as 124I, despite its better physical characters,or the novel hybrid 
imaging modality PET/MRI, have not yet been compared with 131I scintigraphy and SPECT/CT in a 
large series of patients with DTC. These approaches are not yet widely available for clinical use and 
are considered to be primarily research tools at this time [24]. 
10. 99mTc-sestamibi (MIBI) Scan  
It is not unusual that histopathological analysis cannot accurately discriminate benign from 
malignant lesions, since the detection or exclusion of capsular and/or vascular invasion cannot be 
done on cytological specimens in follicular-patterned lesions. As the large majority of such lesions 
are benign, the risk of inappropriate thyroid surgery is significant. In an attempt to address this 
issue, some authors have reported on the role of 99mTc-sestamibi (MIBI) in differentiating malignant 
from benign thyroid lesions in patients with non-diagnostic/indeterminate cytology [50]. At visual 
evaluation, MIBI has a very high NPV in excluding thyroid malignancies, but at the same time a 
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quite low specificity and PPV, since a positive MIBI scan can be found both in malignant and benign 
lesions [51]. The diagnostic accuracy of the MIBI thyroid scan has been proven to increase with the 
usage of quantitative analysis approaches. In particular, Saggiorato first evaluated the 
semi-quantitative Retention Index (R.I.) for the radiotracer, by calculating the ratio between uptake 
within the nodule and the normal thyroid tissue uptake [52]. More recently, other researchers 
introduced another quantitative index for the estimation of the MIBI washout from the nodule, the 
Wash-Out Index (WOind). The main difference between the two parameters lies in the fact that for 
WOind calculations the uptake within normal thyroid tissue, for which washout is faster than that 
within nodules, is not taken into account. Quantitative MIBI scintigraphy by evaluating WOind is a 
useful tool and is documented to be a more accurate method in the management of thyroid nodules 
with indeterminate cytology [53]. To our knowledge there are no available studies with MIBI on 
population ≤18 years of age. Thus, the modality should be implemented with caution in the 
evaluation of the pediatric thyroid nodule. 
11. CT and MRI 
Although US is the primary imaging test for a palpable thyroid nodule or a known thyroid 
malignancy, thyroid abnormalities are frequently first discovered on other cross-sectional modalities 
of CT and MRI. A thyroid lesion may be seen as an incidental finding, or CT and MRI may be used 
for the initial evaluation of an unknown neck mass. Moreover, CT and MRI can play a role in the 
preoperative assessment and staging of a known thyroid malignancy, since they have been 
described to be effective imaging methods for evaluating for nodal metastases and assessing the 
invasion of adjacent anatomical structures. Furthermore, they may aid in the assessment of 
recurrence in the post-treatment neck as well as during follow-up [54], while they are useful in the 
evaluation of potential trachea compression and respiratory compromise. However, an important 
issue associated with the use of CT in children is radiation exposure. The increased application 
nowadays of multidetector row CT scans as well as multiphase CT examinations in pediatric 
medicine raise the issue of high administered doses to the thyroid gland, potentially increasing the 
risk of thyroid cancer. Moreover, the application of iodine-based contrast agents in order to increase 
the sensitivity of the modality leads to suppression of radioactive iodine thyroid uptake, thus 
postponing a potential radioiodine treatment. These facts practically exclude CT scanning from 
screening for thyroid abnormalities and eliminate its role in thyroid cancer’s diagnostic and 
surveillance algorithm [55].  
Regarding MRI, an important advantage is its excellent soft tissue contrast and reduced teeth 
bracelet-related artifacts in the head and neck, as compared to CT and 18F-FDG-PET/CT, rendering it 
the primary imaging modality for soft tissue tumors assessment. MRI of the neck is mainly used for 
planning the surgical approach in head and neck cancer and thyroid cancer patients. Additionally, 
gadolinium-based MRI-contrast media avoids iodine contamination before curative radioiodine 
therapy. Furthermore, radiation exposure is not an issue with MRI. However, similar to CT, MRI is 
not recommended in the routine clinical workup of all thyroid cancer patients of a younger age [56]. 
12. Conclusions 
Although thyroid nodules are less common in children than adults, they pose a higher 
likelihood of malignancy. Thus, once diagnosed, they necessitate an immediate systematic, 
multistep evaluation to define a precise characterization. Thyroid nodules at high risk should be 
evaluated by US and FNA to confirm or exclude DTC, and allow, when appropriate, for complete 
preoperative surgical planning. Low-risk nodules can be followed with serial US and re-interrogated 
by FNA, or removed if they grow or develop suspicious US features. As far as nodules at 
indeterminate risk are concerned, all features, including family and personal history, US 
characteristics, FNA cytology, and molecular testing, should be considered to develop an 
appropriate personalized strategy. The role of nuclear medicine on the management of thyroid 
nodules and cancer in children is vital. The ATA GLs (2015) represent the current optimal care for 
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children and adolescents with thyroid nodules. Taking into consideration that the ATA GL’s task 
force acknowledged the lack of randomized double-blind controlled clinical trials, stating that most 
published data are from retrospective cohorts, potentially subject to investigator bias, the need for 
the conduction of updated guidelines dedicated to patients ≤18 years of age is imperative.  
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CNS Central Nervous System  
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GEC Gene Expression Classifier  
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